KYOTO-SEMICONDUCTOR
5.8.2021 07:02:10 CEST | Business Wire | Press release
Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, announced its collaboration with Semtech Corporation (Nasdaq: SMTC ), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms. Kyoto Semiconductor has chosen to pair their new KP-A avalanche photodiode*1 , KPDEA13C with Semtech’s GN1089 transimpedance amplifier*2 to enable long distance optical communication.
"The pairing of Semtech’s transimpedance amplifier GN1089 with Kyoto Semiconductor’s KPDEA13C was ideal to optimize the performance,” said Tsuneo Takahashi, Kyoto Semiconductor president and CEO. “Through the joint collaboration, the KPDEA13C now includes a fast response suitable for a variety of optical needs.”
Kyoto Semiconductor’s KPDEA13C is front side illuminated, highly sensitive and mounted on an interposer board for ease of assembly. Additionally, Kyoto Semiconductor’s KPDEA13C and Semtech’s GN1089 together offer unparalleled performance at high speed enabling 25Gbaud PAM4*3*4 applications.
"Semtech’s GN1089 is a high performance transimpedance amplifier enabling both 25Gbaud and 56Gbaud applications. Its high linearity and low noise are features that were a perfect fit for the Kyoto Semiconductor, KPDEA13C,” said Timothy Vang, vice president, marketing and applications for Semtech’s Signal Integrity Products Group. “This collaboration with Kyoto Semiconductor showcases the outstanding quality of our solutions for high speed optical communications.”
Sample shipments of KP-A avalanche photodiode, KPDEA13C is scheduled to begin on August 31, 2021, and mass production is expected to start on December 27, 2021.
For evaluation report, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/news/2025/
- English: https://www.kyosemi.co.jp/en/news/1058/
For product datasheet, please visit the following link.
- Japanese: https://www.kyosemi.co.jp/mgt/wp-content/uploads/2021/08/kpdea13c_jp.pdf
- English: https://www.kyosemi.co.jp/en/mgt/wp-content/uploads/2021/08/kpdea13c_en.pdf
For information on Semtech’s GN1089, please visit www.semtech.com/products/signal-integrity/transimpedance-amplifiers/gn1089
*1 Avalanche Photodiode
: Semiconductor Photodiode with photocurrent amplification by applying reverse bias voltage. This photocurrent amplification produces much more current than standard Photodiode. It is useful in the application where the high sensitivity is required.
*2 Transimpedance amplifier
: The circuit or device that convert a current from Photodiode to voltage.
*3 PAM4 (Pulse Amplitude Modulation 4-level)
: A technique of modulation. It uses four voltage levels to represent two bits logic, 00, 01, 10, and 11, against the traditional NRZ modulation uses two voltage levels to represents 1 bit logic, 0 and 1.
*4 25Gbaud PAM4
: PAM4 signal at 25Gbaud modulation speed. It achieves 2 times transmission speed compared with traditional 25Gbaud NRZ signal. i.e., 25Gbaud PAM4 achieves 50Gbps, against 25Gbaud NRZ achieves 25Gbps.
About Semtech’s Optical Products
Semtech’s optical networking product platforms provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure and passive optical network/Fiber to the X (FTTX) markets. For more information, visit https://www.semtech.com/products/signal-integrity
.
About Semtech
Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the NASDAQ Global Select Market under the symbol SMTC. For more information, visit http://www.semtech.com
.
About Kyoto Semiconductor
Kyoto Semiconductor was founded in Kyoto in 1980 as a specialized manufacturer of optical semiconductors. Based on our unique packaging technology, we manufacture semiconductors for optical communications and sensors, which boast high performance and high accuracy, at our own base in Japan with an integrated system from front-end to back-end processes, and supply them to customers around the world. Kyoto Semiconductor is a leader in optical device solutions with Japanese quality manufacturing, leveraging world-class technology. For more information, please. visit https://www.kyosemi.co.jp
.
*Semtech, the Semtech logo are registered trademarks or service marks of Semtech Corporation or its affiliates.
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication. Subject to change without notice. Please understand in advance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005473/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom